Full-Time

Senior Growth Copywriter

Posted on 9/9/2026

Seed Health

Seed Health

201-500 employees

Develops and sells probiotic microbiome products

Compensation Overview

$145k - $165k/yr

+ Equity

Remote in USA

Remote

Category
Content & Writing (1)
Required Skills
Data Analysis

Get referred to Seed Health

See people who can refer or advise you

Requirements
  • Five to eight years of agency or brand-side writing experience.
  • A portfolio including real, running paid social and performance work rather than only speculative advertisements or brand campaigns.
  • Ability to write hooks and headlines quickly while maintaining quality.
  • Comfort reading performance metrics and using them to shape creative decisions.
  • Curiosity about culture and the platforms where the work appears.
  • Experience working on productions ranging from quick-turn user-generated-content-style shoots to campaign-level work.
  • Ability to move between macro-level campaigns and individual ad variations.
Responsibilities
  • Develop performance-driven concepts, hooks, scripts, headlines, supers, primary text, and calls to action across television, Meta, TikTok, and YouTube, considering how messaging comes to life within the full advertisement.
  • Generate large sets of testable copy variations for an always-on testing cadence, working with media buyers and performance marketers to understand what is working and why.
  • Use hook rate, click-through rate, conversion rate, and cost per acquisition data to inform subsequent copy.
  • Apply growth-minded copy to landing pages, email, SMS, and other conversion touchpoints in addition to top-of-funnel advertising creative.
  • Maintain a consistent, clear, and on-brand Seed voice in performance copy.
  • Review advertising scripts and copy from agencies and external partners, providing actionable feedback to ensure the work is on-brand, strategically sound, and performance-oriented.
  • Partner with art directors, designers, motion designers, growth marketers and strategists, and cross-functional partners to ship and iterate work quickly.

Seed Health develops and sells probiotic and microbiome-based consumer products for humans and pets through its online store. Formulations are grounded in scientific research, tested for safety and effectiveness, and shipped directly to customers. The company differentiates itself by pairing rigorous science with education and transparent communication, while pursuing a direct-to-consumer model and a broader focus on planetary health. Its goal is to improve human and planetary health by making microbiome science actionable and accessible for everyday wellness.

Company Size

201-500

Company Stage

Series A

Total Funding

$40M

Headquarters

Los Angeles, California

Founded

2016

Get referred to Seed Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • January 14, 2026 Nutrients data showed DS-01 reduced bloating and improved regularity.
  • May 20, 2026 Seed hired Anisha Raghavan as first CMO to accelerate retail growth.
  • PitchBook shows $43.8 million raised, while Seed’s 2025 profile marked generating revenue.

What critics are saying

  • BBB listed 160 complaints in three years, signaling recurring customer dissatisfaction and support strain.
  • Ritual, Transparent Labs, and Pendulum attack Seed’s pricing, transparency, and strain-selection narrative.
  • Supplements remain exposed to FDA claim scrutiny; one adverse ruling can cripple marketing economics.

What makes Seed Health unique

  • Seed pairs consumer branding with microbiome clinical trials and patented ViaCap delivery.
  • Jacques Ravel’s vaginal microbiome research anchors VS-01 and its 2025 optimal-CST I data.
  • Seed sold DS-01 in Target, Amazon, and direct-to-consumer by 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Company Match

Mental Health Support

Wellness Program

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Business Insider
May 20th, 2026
Seed Health appoints first CMO to scale microbiome startup beyond niche market

Seed Health, a microbiome science company that sells pre- and probiotics, has appointed Anisha Raghavan as its first chief marketing officer. Raghavan will focus on growing the company's retail presence, product mix and brand awareness. Founded in 2016, Seed Health has raised around $40 million from investors including Founders Fund and celebrities such as Gwyneth Paltrow and Cameron Diaz. The company has grown revenue by over 500% in the past three years and now sells through Target and Amazon alongside its direct-to-consumer channel. Raghavan, whose experience includes running multibillion-dollar brands at PepsiCo and Unilever, plans to scale through unexpected partnerships, interactive advertising and quality influencer collaborations. All creators working with Seed must pass a gut health science test through its Seed University programme.

PR Newswire
Apr 21st, 2026
Seed Health launches Resilient Soils Project to explore microbial solutions for PFAS contamination

Seed Health and The Two Frontiers Project have launched The Resilient Soils Project, a community science initiative investigating how microbes adapt to chemically impacted environments. The project explores whether microbial life is developing natural responses to "forever chemicals" like PFAS that could inform new remediation approaches. The initiative invites individuals to collect soil samples from contamination sites for metagenomic sequencing. Results will contribute to 2FP's Living Database, an open-access archive providing researchers with DNA sequencing data from chemically impacted environments. Under sustained chemical pressure, soil microbes can evolve metabolic pathways capable of transforming or breaking down contaminants. Previous Seed and 2FP collaborations have generated over 1,000 environmental data points, uncovering microbial communities with potential applications in carbon capture and coral reef resilience.

PR Newswire
May 5th, 2025
Seed Health Presents New Clinical Trial Data: Ds-01® Increases Two Key Microbiome Molecules Linked To Gut, Metabolic, Immune, And Cellular Health

DS-01® is the first broad-spectrum synbiotic clinically shown to increase production of both Urolithin A and butyrate—two key microbial metabolites linked to whole-body healthPresented at Digestive Disease Week® (DDW) 2025, the findings expand DS-01®'s clinical foundation and reinforce the potential of microbiome-targeted products to impact multiple biological systemsBOSTON, May 5, 2025 /PRNewswire/ -- Microbiome science company Seed Health presented clinical data on its flagship innovation, DS-01® Daily Synbiotic, at Digestive Disease Week® (DDW) 2025. Findings from a randomized, placebo-controlled clinical trial in healthy adults demonstrated that DS-01® increased production of two key microbial metabolites—Urolithin A and butyrate—implicated in gut barrier function, metabolism, and healthy aging. The trial also found reductions in C-Reactive Protein (CRP), a widely used marker of systemic inflammation, suggesting DS-01®'s potential to influence immune pathways. The findings underscore DS-01®'s impact beyond microbial composition, demonstrating measurable biological function through the production of microbiome-mediated metabolites.The company presented two posters during the "Prebiotics, Probiotics and Synbiotics in Health and Disease" session.Presentation HighlightsEffects of a novel, broad-spectrum synbiotic on Urolithin A production: A randomized, placebo-controlled clinical trialThis randomized, placebo-controlled clinical trial evaluated DS-01® for its ability to increase production of Urolithin A—a microbiome-derived metabolite linked to mitochondrial function, cellular energy, metabolic health, intestinal barrier integrity, and healthy aging. DS-01® provides the natural machinery to produce Urolithin A, delivering both a polyphenol precursor in its prebiotic outer capsule and key microbes in its probiotic inner capsule.Overall, this is the first study to demonstrate that a broad-spectrum synbiotic can increase Urolithin A production in humans. Key findings include:Rapid and Sustained Urolithin A Increase: DS-01® increased urinary Urolithin A levels by approximately 100-fold by Day 7 (P<0.0001), with levels sustained through Day 91.DS-01® increased urinary Urolithin A levels by approximately 100-fold by Day 7 (P<0.0001), with levels sustained through Day 91

Pressed Juicery
Aug 8th, 2024
I Tried Seed Health's New Vaginal Probiotic-Here's Why You Should Too

(In fact, one of its editors previously covered the Daily Synbiotic at The Chalkboard Mag) But it wasn't until Seed Health launched its VS-01(TM) Vaginal Synbiotic that I decided to give the brand a try to rebalance my microbiome and the rest of my system.

PR Newswire
Aug 1st, 2024
New Clinical Data Highlights Efficacy Of Seed Health'S Vs-01 Vaginal Synbiotic In Establishing Protective And Optimal Vaginal Microbiome

The study, which is the first to show that a multi-strain vaginal synbiotic can establish a protective vaginal environment, will be presented at the Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG)The data demonstrate that VS-01™ successfully cultivates a vaginal microbiome dominated by Lactobacillus crispatus, reduces harmful microbes, and combats vaginal dysbiosisThese results underscore the potential of the vaginal microbiome and microbiome-directed innovations to redefine standards of care in women's healthBOSTON, Aug. 1, 2024 /PRNewswire/ -- Seed Health will present new clinical data on its flagship vaginal microbiome innovation, VS-01™ Vaginal Synbiotic, at the upcoming 2024 Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting. Data from a randomized, placebo-controlled clinical trial demonstrated the superior efficacy of VS-01™ in cultivating a stable and healthy vaginal microbiome. The synbiotic successfully established a protective environment dominated by Lactobacillus crispatus and inhibited harmful microbes associated with vaginal dysbiosis and inflammation. These findings highlight the transformative potential of proactive, preventive care centered on the vaginal microbiome, shifting the focus from traditional symptom management to maintaining a balanced and resilient vaginal ecology.A landmark 2012 study from vaginal microbiome researcher Jacques Ravel, Ph.D., demonstrated that the most stable and optimal vaginal microbiome is characterized by a dominance of the bacterium Lactobacillus crispatus, which plays a protective role in maintaining vaginal health. However, everyday factors such as menstruation, sexual activity, exercise, stress, contraceptives, and cleansers can deplete the abundance of L